MEDICARE PART B CMS Should Take Additional Steps to Verify Accuracy of Data Used to Set Payment Rates for Drugs.

UNITED States. Government Accountability Office; CENTERS for Medicare & Medicaid Services (U.S.); PATIENT Protection & Affordable Care Act; HEALTH insurance; UNITED States. Congress; MEDICARE Part B

The article discusses the study conducted by the U.S. Government Accountability Office (GAO) regarding medicare. GAO examined Medicare spending for and utilization of Part B drugs and the accuracy of the sales price data reported by drug manufacturers. GAO suggests that the U.S. Congress should consider requiring all manufacturers of drugs paid at average sales price (ASP) to submit sales price data to U.S. Centers for Medicare & Medicaid Services (CMS).